Molecular defect (Gla+ 14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X" Vorarlberg"). by Watzke, Herbert et al.
THE JOURNAI. OF BIOLOGKXL. CHEMISTRY 
0 1990 by The American Society for Biochemistry and Molecular Biology, Inc. 
Vol. 265, No. 20, Issue of July 15, pp. 11982%11989,1990 
Printed in U.S.A. 
Molecular Defect (Gla+14 +Lys) and Its Functional Consequences in a 
Hereditary Factor X Deficiency (Factor X “Vorarlberg”)* 
(Received for publication, November 21, 1989) 
Herbert H. Watzke$, Klaus Lechnert, Harold R. Roberts& Sakamuri V. Reddyn, Dean J. Welschlj , 
Paul Friedman11 , Gert Mahr**, Pudur Jagadeeswaranq, D. M. Monroe& and Katherine A. Highs $$ 
From the $Departments of Medicine and Pathology, and Center for Thrombosis and Hemostasis, University of North Carolina, 
Chupel Hill, North Carolinu 27599, IjMerck, Sharp, cmd Dohme Reseurch Laborutories, West Point, Pennsylvunia 19486, 
YlDepurtment of Celhdur und Structural Biology, Uniuersity of Texas Health Sciences Center, Sun Antonio, Texas 78284, §First 
Department of Medicine, University of Vienna, Vienna A-1090 and **Municipal Hospital, Feldkirch A-6800, Austria 
Factor X (FX) “Vorarlberg” is a congenital FX defi- 
ciency characterized clinically by a mild bleeding tend- 
ency. Homozygous individuals have a FX activity of 
less than 10% in the extrinsic system and 25% in the 
intrinsic system. FX antigen is 20%. Using molecular 
techniques, two point mutations were detected in the 
coding sequence of the FX Vorarlberg gene: a G+A at 
base pair 160 in exon II resulting in a change of Gla14 
(GAA) to Lys (AAA); a G+A at base pair 424 in exon 
V resulting in a change from Gluloz (GAG) to Lys 
(AAG). The mutations abolished a TaqI restriction site 
in exon II and an MnlI site in exon V. To determine 
whether these mutations are present on one or on both 
alleles, restriction analyses of amplified exon II and 
exon V fragments were performed. Analysis of the 
pedigree showed that the genotype for the mutation on 
exon II (homozygous versus heterozygous) correlates 
with the severity of the phenotypic coagulation defect. 
We therefore conclude that the mutation in exon II is 
responsible for the functional defect in FX Vorarlberg. 
We have also purified the mutant FX protein from 
patient plasma. Purified FX Vorarlberg is indistin- 
guishable from normal FX on sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis. Its activity is 15% 
of normal FX upon activation with factor VIIa/tissue 
factor, 75% upon activation with factor IXa/factor 
VIIIa, and 100% upon activation with RVV. Activation 
at varying Ca2+ concentrations shows that the affinity 
of FX Vorarlberg for Ca2+ is decreased. Factor Xa 
Vorarlberg is able to convert prothrombin at a normal 
rate but also shows decreased affinity for Ca2+ in this 
interaction. Upon addition of Ca2+, FX Vorarlberg does 
not undergo the same conformational change as normal 
FX. Our data show that FX Vorarlberg has a decreased 
affinity for Ca2+ which impedes a normal conforma- 
tional change. This leads to a decreased rate of acti- 
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vation by factor VIIa/tissue factor and by factor IXa. 
The decrease is much more marked for the extrinsic 
than for the intrinsic pathway. 
Factor X (FX) is a plasma glycoprotein required in both 
the intrinsic and extrinsic pathways of blood coagulation (1). 
It is synthesized in hepatocytes as a single polypeptide chain; 
following several post-translational modifications, including 
glycosylation, vitamin K-dependent carboxylation of the y- 
carbon of the first 11 glutamic acid residues, and cleavage of 
the leader sequence, the mature protein is secreted into the 
circulation. FX circulates as a two-chain zymogen composed 
of a light chain (Mr 16,200) and a heavy chain (Mr 42,000) 
joined by a single disulfide bond (2). The light chain of FX 
contains the 11 T-carboxyglutamic acid residues, 1 residue of 
/?-hydroxyaspartic acid, and two growth factor-like domains, 
which show sequence similarity with epidermal growth factor. 
The heavy chain contains the activation peptide and the 
catalytic domain. A single arginine-isoleucine bond is cleaved 
in the heavy chain of FX by both the intrinsic and the 
extrinsic pathways of blood coagulation, generating factor Xa 
(FXa) and a small activation peptide (3). This reaction is 
catalyzed by factor IXa (FIXa) and its cofactor VIIIa (FVIIIa) 
in the intrinsic system and by factor VIIA (FVIIa) and its 
cofactor tissue factor (TF) in the extrinsic system. Both 
reactions require calcium ions and phospholipids (4, 5). 
The amino acid sequence for human FX has been derived 
from FX cDNAs and direct amino acid analysis (6-9). The 
gene has also been isolated and partially characterized. It has 
been mapped to chromosome 13q32-qter (lo), where it spans 
approximately 25 kilobases. Although still incompletely char- 
acterized, it consists of seven introns and eight exons and 
shows considerable structural homology with the genes en- 
coding the other vitamin K-dependent clotting factors (11). 
The functional domains of the protein are represented by 
different exons: exon I codes for the signal peptide region, 
exon II for the propeptide and the T-carboxyglutamic acid- 
rich domain, exon III for the short aromatic acid-rich stack, 
exon IV for the first epidermal growth factor domain, exon V 
for the second epidermal growth factor domain, exon VI for 
the activation peptide, and exons VII and VIII for the catalytic 
domain. The splice junction sites follow the GT/AG rule, 
include type 1 and type 0 junctions, and delineate seven 
introns ranging in size from 950 to 7400 nucleotides (11). The 
human FX mRNA consists of approximately 1500 nucleotides 
including a coding region of 1475 bases and a short 3’- 
untranslated region of 10 nucleotides (8). The polyadenylation 
signal (ATTAAA) is located in the coding sequence and 
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precedes the stop codon by one nucleotide. The 5’ end of the 
mRNA has not been characterized. 
Congenital FX deficiency is inherited as an autosomal 
recessive trait (12). Considerable phenotypic heterogeneity 
exists among factor X variants. This is evident both structur- 
ally, with patients reported to have normal, reduced, or absent 
antigen levels (13, 14), and functionally, as evidenced by the 
variety of patterns seen following activation of abnormal 
Factor Xs in either the intrinsic or the extrinsic system (15). 
FX variants which exhibit different activities in the extrinsic 
uersus the intrinsic system are of particular interest, since 
little is known about the mechanisms by which Factor X is 
activated by IXa/VIIIa or VIIa/TF. In this work, we report 
the molecular basis of a new FX variant, FX “Vorarlberg,” 
using DNA sequence analysis. Further, we characterize the 
functional defect of the isolated FX Vorarlberg protein. The 
mutation at the Gla residue results in a protein with decreased 
ability to bind calcium. This decrease appears to account for 
its altered function. 
EXPERIMENTAL PROCEDURES 
P&e& &la-Blood samples were obtained after informed consent 
tram eight members (Fig. 1) of a FX-deficient family living in a 
remote valley in the mountain area of Vorarlberg, Austria. FX deli- 
ciency was detected m III/9 at a routine preoperative coagulation 
screening. Past history was notable only for mild bruising since 
childhood. Tooth extractions, an appendectomy, and a hysterectomy 
had been performed without any apparent bleeding tendency. 
Isolation and Charactematlon of Mutant Factor X Gene-Genomic 
DNA was prepared from the patients’ peripheral blood using standard 
methods (16), and Southern blots were performed to determine 
whether the mutant gene was grossly intact (17). Ten pg of genomic 
DNA from a patient (III/4 in Fig. 1) and from a nonrelated normal 
control were digested with 30 units of EcoRI at 37 ‘C for 3 h. The 
DNA was electrophoresed on a 0.8% agarose gel and transferred to a 
FIG. 1. Pedigree of FX VorarIberg and corresponding re- 
striction enzyme digests of amplified exon II and V fragments. 
Exon II and V fragments, carrying the restriction site with the point 
mutations in question, were enzymatically amplified, digested with 
7’a9I (for exon II) or MnlI (for exon V) and run on a 6% agarose gel. 
Genotype for the mutation in exon II: in the three phenotypically 
homozygous family members (III/l, IIIf4, III/g) a homozygous gen- 
otype for the mutation in exon II was detected as indicated by the 
single band at 185 bp (representmg copies of exon II which cannot 
be cut with 7’0~1 and therefore are copies from mutant alleles). The 
five phenotypically heterozygous family members (IV/l, IV/5, IV/g, 
IV/IO, IV/ll) exhibit a heterozygous genotype for the mutation in 
exon II as indicated by the three bands: a band at 185 bp (uncut 
fragment. copied from a mutant allele); bands at 101 and 84 bp (cut 
fragment, copied from a normal allele). Genotype for the mutation in 
exon V: all family members are heterozygous for the mutation in exon 
V regardless of their phenotype as indicated by three bands: a band 
at 149 bp (uncut fragment, copied from a mutant allele); bands at 91 
and 58 bp (cut fragment, copied from a normal allele). 
nitrocellulose membrane according to the method of Southern (17). 
A FX cDNA was radiolabeled with [“‘P]dCTP by priming with 
random hexanucleotides, using the manufacturer’s conditions (Boeh- 
ringer-Mannheim). Twenty ng of labeled probe with a specific activity 
of 1.8 x 10” were added to the filter, incubating in 6 x SSC (where 
SSC is standard saline citrate), 0.01 M EDTA, 0.1 M KHZPOq, 5 X 
Denhardt’s solution, 0.5% SDS,’ and 250 pg/rnl salmon sperm DNA. 
After incubation for 12 h at 68 ‘CZ the filter was washed in 2 X SSC. 
0.5% SDS twice for 15 min at room temperature, in 0.1 X SSC] 0.5% 
SDS for 45 min at 68 ‘C and exposed to x-ray film at -70 ‘C for 24 
h. 
All eight exons of FX were isolated using the enzymatic amplifi- 
cation technique (18). Synthetic oligonucleotides derived from pre- 
viously published intron sequences flanking the <5’ and 3’ ends of 
each exon (19) were used to prime amplification (Table I). Hind111 
restriction sites were built in at the 5’ ends of each oligonucleotide 
(underlined in Table I). Target sequences were amplified in a 100.~1 
volume containing 1 pg of genomic DNA, 10 mM Tris-HCI, pH 8.3. 5 
mM MgCl?, 0.1% (w/v) gelatin, 1.5 !.LM of each deoxyribonucleotide 
(dNTP:dCTP, dGTP, dATP, dTTP), 1 jiM of each primer, and 1 unit 
of 7’aq polymerase. The samples were overlaid with 100 ~1 of mineral 
oil to prevent condensation and subjected to 30 cycles of denaturation 
at 94 ‘C for 2 min, annealing at 55 OC for 2 min and primer extension 
at 70 OC for 3 min in a DNA Thermal Cycler R (Perkin-Elmer Cetus 
Instruments). The amplified DNA was electrophoresed on a 2Y 
agarose gel in TrisborateEDTA buffer (TBE) and the gel fragment 
containing the amplified sequence cut out. The recovered gel slice 
was ground and incubated with 50 ~1 of TBE, 50 ~1 of phenol, and 50 
~1 of chloroform:isoamyl alcohol (24:l) for 15 min at -70 ‘C. After 
centrifugation for 15 min in a microcentrifuge, the supernatant was 
recovered and the DNA precipitated with ethanol. After digestion 
with HmdIII, the fragments were subcloned into Ml3 sequencing 
vectors and sequenced as previously described (20). Exons I, III, IV, 
VI, VII, and VIII were sequenced in both orientations from a single 
PCR amplification for each exon. Exons II and \’ were sequenced 
twice in each orientation using four different subclones from three 
different amplifications. Exon II and exon V were also amplified as 
described above to perform restriction analysis. Thirty-base synthetic 
oligonucleotides derived from the exon and part of the intron were 
used in this amplification to yield an exon II fragment of 18,5 bp 
containing a single TayI site (Fig. 2) and an exon V fragment of 149 
bp containing a single MnlI site (Fig. 3). Fragments were electropho- 
resed and purified as described above. Digestions were carried out 
according to the manufacturers’ conditions with TaoI for the ampli- 
fied exon II fragment and with M&I for the exon V fragment. Digests 
were electrophoresed on a 6% agarose gel (Nu SieveR GTG. FAMC 
Bio Products, Rockland, ME) in TBE buffer. Exon II and V amplified 
from normal DNA were used as controls in all restriction digests. 
Protein.? 
Protein Purification and Analysis 
FX Vorarlberg was isolated after informed consent from patient 
III/9 (Fig. l), who is homozygous for the causative mutation in the 
Gla domain (Gla”+Lys) and heterozygous for the presumed poly- 
morphic site in the second epidermal growth factor-like domain 
(Glu”“+Lys). Normal FX was isolated from outdated frozen normal 
human plasma. Plasma was thawed at 37 ‘C and barium chloride (1 
M) was added to a final concentration of 0.1 M. Barium precipitate 
was collected after centrifugation and washed twice in 0.1 M BaC&, 1 
mM benzamidine-HCl (three times the original plasma volume). The 
barium precipitate was eluted with 45% saturated ammonium sulfate, 
1 mM benzamidine (one-tenth original plasma volume). The eluate 
was dialyzed against 3 X 1 liter of 50 mM Tris-HCl, pH 7.4, 1!50 rnM 
NaCl, 0.1% polyethylene glycol 8000 (PEG), 1 mM benzamidine 
overnight. FX was isolated from the Ba’+ citrate eluate by immu- 
noaffinity chromatography using either a mouse monoclonal (gift of 
Dr. William Church and Dr. Kenneth Mann, University of Vermont 
(Ref. 21)) or a rabbit polyclonal anti-human FX antibody coupled to 
an Affi-Gel 10 matrix. The rabbit calcium-dependent anti-human 
factor X antibody was made from the plasma of a rabbit injected with 
human factor X. The calcium-dependent antibody was purified by 
’ The abbreviations used are: SDS, sodium dodecyl sulfate: bp, base 
pair; RVV, Russell’s viper venom; PT, prothrombin time; aPTT, 
activated partial thromboplastin time; DAPA, dansylarginine-N-(3- 
ethyl-1,5-pentanediyl)amine. 
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TABLE I 
Nucleotide oligomers used to amplify fuctor X exons 
Ifind restriction sites designed into oligomers are underlined. 
5’ Oligomer EXOll 3’ Oligomer 
GACAACAGCCATCCAAGCTT- 1 CTGCCGCCCCTCCAAGCTTC- 
GGGCGTGGAC CTGGCGCTGC 
CAGGAAGCTTAGGTGAGGGG- 2 ACGAAGCTTCAGGGCCAGCG- 
GAGCCTGGGT AGGG 
TCTAAGCTTTCCTTTTAG 3 ATAAGCTTATCCTGATGAAC- 
CCCTCTCACT 
GTTATCTGAAGCTTAGGGCC- 4 TCAAAGCTTCCCCCGCCCAC- 
AAGGTTAGCA CTGCCAC 
CCAGCCAAGCTTCCATTTCT- 5 ACAAGCTTGTGTCCCCACCC- 
CCAGCTGTCC CCTG 
GCAAGCTTTGGGGAGCCTCT- 6 GAGGTGCAAAGCTTGACAGG- 
CTCTGTGCTG TGGTCTCTCC 
GGATGGAAGCTTACCGAAGA- 7 GGTTTCTGAAAAGCTTACAG- 
GGAC TGACGGTGCC 
AGCAAGCTTTGTGCGAGAGC- a AAGGGCGGAAGCTTGTGTTC- 
ATGTCCCTGG CAGACAGACA 
5’ -CTC GAA AGA -  3’ 5’ -CTC GAA AGA -  3’ 
4 
5’ XTC AAA AGA -  3’ + 
Lw m Arg 
5’ -UC AAA AGA -  3 
K T 1 
FIG. 2. Sequence of the point mutation in exon II. A G-A 
mutation in the first base of the codon for the y-carboxylated residue 
GltY (GAA) leads to an amino acid change to Lys (AAA). The 
mutation abolishes a naturally occurring TaoI restriction site with 
the sequence TCGA. 
4 
S 4AC AAG GAA-3 4 5’ -  CAC AM GAA -3’ 
HIS m Glu 
M 
FIG. 3. Sequence of the point mutation in exon V. A G-A 
mutation in the first base of the codon for Gl#” (GAG) leads to an 
amino acid change to Lys (AAG). The mutation abolishes a naturally 
occurring MnlI site with the sequence (n7) GAGG. 
passing rabbit serum through a column of factor X-Affi-Gel 10 in the 
presence of 10 mM CaCIZ. Antibody was eluted from the column with 
IO mM EDTA. The Ba’+ eluate was passed through the column at 10 
ml/h. The column was washed with 50 mM Tris-HCI, pH 7.4, 150 
mM NaCl, 0.1% PEG, until the 280-nm absorbance returned to base 
line. Factor X was eluted with 3 M sodium thiocyanate, 50 mM Tris- 
HCl, pH 7.4. The purified protein was dialyzed into 50 mM Tris-HCl, 
pH 7.4, 150 mM NaCl, 0.1% PEG, and stored frozen. 
Concentration of FX-Concentration of FX (Vorarlberg and nor- 
mal) was determined by absorbance at 280 nm (extinction coefficienti 
1.16 ml x mg-’ x cm-‘) corrected for light scattering by measuring 
absorbance at 320 nm. 
Actiue Site Z’itration of Factor Xu-This was performed as previ- 
ously described (22) using p-aminobenzamidine. After activation of 
FX, 10 rig/ml heparin was added. Small microliter additions of 
antithrombin III were made, and the fluorescence decrease at 376 nm 
(excitation at 336 nm) was monitored. The amount of antithrombin 
III required to displace all of the p-aminobenzamidine from the active 
site is equal to the concentration of the active enzyme. 
Factor IX-FIX and prothrombin were isolated from barium chlo- 
ride-precipitated plasma using DEAE-cellulose and dextran-sulfate 
agarose columns as previously described (23). 
Factor VIIIa (FVIIIa)-Two different procedures were used to 
generate FVIIIa from a commercially available FVIII preparation 
(Monoclate, Armour Pharmaceuticals). In one procedure, 86 nM FVIII 
was incubated with 5 nM thrombin at room temperature for 10 min 
in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% PEG. The reaction 
was stopped by addition of the thrombin inhibitor Phe-Pro-Arg- 
chloromethyl ketone to a final concentration of 20 pM. Thrombin- 
activated FVIII was used when the consecutive activation of FX (by 
FIXa and FVIIIa) was monitored by a chromogenic substrate. To 
avoid any carryover of Phe-Pro-Arg-chloromethyl ketone in the final 
activation, FVIII was activated with FXa when the consecutive acti- 
vation of FX was monitored by the conversion of prothrombin to 
thrombin. In this activation 86 nM FVIII was incubated with 1.5 nM 
of FXa (activated with RVV) at room temperature for 15 min in 50 
mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% PEG. 
Thrombin-Human prothrombin was activated by the prothrom- 
bin activator of E. carinutus coupled to an Affi-Gel 10 matrix. Throm- 
bin was then isolated using an SP ZetaPrep 15 chromatography disc 
as described elsewhere (24). 
Human Factor V and Factor V Coagulunt Protein from Russell’s 
Viper Venom-These proteins were a generous gift of Drs. Barry 
Lentz, Daniel Powers, and Gwyn Cutsforth, University of North 
Carolina, Chapel Hill. 
Human (Recombinant) FVIIa (Nia.stase)-This was a generous gift 
from Novo Industries. 
Polyacrylamide Gel Electrophoresis 
Polyacrylamide gel electrophoresis was performed using the tech- 
niques of Laemmli as modified by LeStourgen and Beyer (25). The 
gels were stained by a silver stain procedure (26). 
Coagulation Assays 
One-stage clotting assays were used to determine FX activity of 
FX Vorarlberg plasma and isolated FX Vorarlberg (27). All clotting 
assays were performed on a Fibrosystem fibrometer. FX activity was 
determined using assays based on the prothrombin time (PT) and 
the activated partial thromboplastin time (aPTT) using standard 
methods. Activation with Russell’s viper venom was performed ac- 
cording to previously published methods (28) using a crude RVV 
preparation (Sigma). 
Coagulunt Activity of FX (Vorarlberg and Norma0 
Prothrombin Time-For the analysis of FX activity in the extrinsic 
pathway, 100 ~1 of FX was incubated for 3 min at 37 ‘C. At tbe end 
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of the incubation time, 200 ~1 of 3’7 “C thromboplastin (rabbit brain) 
was added, and, simultaneously, the fibrometer timer was started. FX 
clotting activity was measured in plasma (normal or Vorarlberg) that 
was serially diluted (1:20 to 1:320) into FX-deficient plasma. For 
assays of purified factor X, samples were prepared by incubating 60 
~1 of FX-deficient plasma and 40 ~1 of various concentrations of pure 
FX (normal or Vorarlberg) in 50 mM Tris-HCl, pH 7.4,150 mM NaCl, 
0.1% PEG. A standard curve was generated with normal FX and the 
activity of FX Vorarlberg was expressed as a percentage of normal 
FX. 
aPZ’T-For the analysis of the FX activity in the intrinsic pathway, 
100 ~1 of plasma (normal or FX Vorarlberg) was incubated with 100 
~1 of human FX-deficient plasma and 100 ~1 of aPTT reagent for 3 
min at 37 *C. At the end of the incubation time, 100 ~1 of CaCl* (25 
mM) was added, and, simultaneously, the fibrometer timer was acti- 
vated. FX was measured in plasma (normal or Vorarlberg) that was 
serially diluted (1:20 to 1:320) into FX-deficient plasma. For assays 
of purified FX, the concentration of FX (normal or Vorarlberg) in 50 
mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% PEG was varied. A 
standard curve was generated with normal FX and the activity of FX 
Vorarlberg expressed as a percentage of normal FX. 
RVV T&lFor the anilysis of-FX activity after activation with 
RVV. FX was incubated with 100 ul of FX-deficient nlasma and RVV 
(0.1 ig/ml) for 30 s at 37 ‘C. At ihe end of the incibation time, 100 
~1 of CaCIZ (25 mM) was added simultaneous to activating the fibro- 
meter timer. For assays of plasma, 100 ~1 of plasma in serial dilutions 
(1:20 to 1:320) into FX-deficient plasma and 100 ~1 of RVV were 
used. For assays of purified FX, 50 il of RVV with 5 ~1 of Thrombofax 
reagent and 45 ~1 of FX (normal or Vorarlberg) in 50 mM Tris-HCl. 
pH>.4,150 mM’NaC1, 0.1% was used. A standa;dcurve was generatei 
with normal FX and the activity of FX Vorarlberg expressed as a 
percentage of normal FX. 
FX Antigen Leuek in FX Vorarlberg Plasma-These were deter- 
mined by the method of Laurel1 (29) using a polyclonal rabbit anti 
human FX antibody (produced in the laboratory of Dr. K. Lechner, 
Department of Medicine, University of Vienna). 
Chromogenic Substrate Assay 
The FXa-specific chromogenic substrate Spectrozyme FXa (Amer- 
ican Diagnosiica) was used to monitor the a&ivatioi of FX (normal 
and Vorarlberg) by FVIIa/TF, by FIXa/FVIIIa and bv RVV, respec- 
tively. The &re&e in ibsoib&ce oi the p-nitroinilide .pro&ct 
released when FXa cleaves Spectrozyme FXa was measured at 404 
nm with a Perkin-Elmer Lambda 3 dual-beam spectrophotometer. 
Activation of FX (Normal and Vorarlberg) by FVIIa/TF-Fifteen 
nM FX (normal or Vorarlberg) were incubated with 250 pM Spectro- 
zyme FXa and 5 J.Z~ of Thrombotest (Ortho Diagnostics) as a source 
01 tissue factor in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM 
CaCl?. 0.1% PEG for 30 s at room temnerature. The activation of FX 
was sTarted by the addition of 0.7 nM iure FVIIa. 
Activation of FX (Normal and Vorarlberg) by FIXa/FVIIIA- 
Fifteen nM FX (normal or “Vorarlberg”) was incubated with 250 pM 
Spectrozyme FXa, 3 nM FIXa, 50 nM FVIIIa, 10 pM phospholipid 
vesicles in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% PEG for 3 
min at room temperature. Phospholipid vesicles (50% phosphatidyl- 
serine, 50% phosphatidylcholine) were prepared by reverse-phase 
evaporation (30). The activation of FX was started by the addition 
Of 5 mM CaCIZ. 
Actiuation of FX (Normal and VorarlbergJ by RVV-Fifteen nM 
FX (normal or Vorarlberg) was incubated with 250 &M Spectrozyme 
FXa, 0.5 rig/ml RVV, in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 
0.1% PEG for 30 s at room temperature. The activation of FX was 
started by the addition of 5 mM CaC&. 
All activations were performed at a CaCl* concentration of 5 mM 
(as described above) and at CaCl* concentrations ranging from 5 to 
0.5 mM. 
Prothrombin Conversion by FXa 
The thrombin-specific fluorescent substrate DAPA was synthe- 
sized by the procedure of Nesheim et al. (31) and was used to monitor 
the conversion of prothrombin to thrombin by FXa. FX (normal and 
Vorarlberg) was f&t activated to FXa by FVIia/TF, by FIXa/FVIIIa, 
and by RVV as outlined above (without the addition of Snectrozvme 
FXa)..To allow complete activation of FX, reactions weri run foi 60 
min at room temperature. One-hundredth nM of FXa (normal or 
Vorarlberg) was incubated with 1.2 nM FV, 0.15 rig/ml Factor V- 
coagulant protein from Russell’s viper venom, 1 pM phospholipid 
vesicles (phosphotidylserine/phosphotidylcholine = l:l), 0.5 pM 
DAPA in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5 mM CaCIZ, 
0.1% PEG for 2.5 min at room temperature. The reaction was started 
by the addition of prothrombin to a final concentration of 120 nM. 
The increase in fluorescence when DAPA binds to the thrombin 
generated by the subsequent activation of prothrombin by FXa was 
measured with a Perkin-Elmer LS-5 spectrofluorometer with an 
excitation wavelength of 280 nm (lo-mm slit) and an emission wave- 
length of 565 nm (20-mm slit) with a 450-nm cutoff emission filter. 
Intrinsic Fluorescence Quenching 
Quenching of the intrinsic fluorescence upon addition of Ca*+ was 
measured according to the method of Nelsestuen (32) and Prendergast 
and Mann (33). Small microliter additions of 100 PM CaCIZ were 
made to 100 pg/ml of FX (normal or Vorarlberg) in 50 mM Tris-HCl, 
pH 7.4,150 mM NaCl, 0.1% PEG. The emission spectrum of the FX 
(normal or Vorarlberg) upon addition of Ca*+ was monitored at each 
Ca*+ concentration (after a 2-min incubation) using a Perkin-Elmer 
LS-5 spectrofluorometer with an excitation wavelength of 280 nm 
(lo-mm slit) and an emission wavelength of 340 nm (20-mm slit). 
Gla Analysis 
Gla analysis was done according to the method of Price (34). 
Data Analysis 
Both the Perkin-Elmer Lambda 3 dual-beam spectrophotometer 
(Spectrozyme FXa assays) and the Perkin-Elmer LS5 fluorometer 
(p-aminobenzamidine and DAPA assays and intrinsic fluorescence 
measurements) were coupled to a dedicated HP 85 microcomputer. 
Time course data were sampled using a Hewlett-Packard HP347OA 
analog-digital converter. For coupled assays using Spectrozyme FXa, 
the rate of factor X activation was determined from the slope of the 
line obtained by plotting the change in the 404-nm absorbance (A.& 
uersus the time of the reaction (23). For prothrombin activation 
assays using DAPA, the rate of thrombin-activation was determined 
from the slope of the line fit to the initial values of a plot of 
fluorescence versus time (33). 
RESULTS 
screening Coagulation Assays in the Kindred 
The index case (111-9 in Fig. 1) was found to have a FX 
activity level of 5% using a PT-based assay. Therefore, other 
family members were screene& 111-l and III-4 also had low 
levels, 4.5 and 7.5%, respectively; members of generation IV 
had higher FX activity levels, all approximately 50% (IV-l, 
51%; IV-5,54%; IV-g, 54%; IV-lo, 48%; IV-11,65%). Family 
members with FX activity levels of <lo% (III-l, 111-4, 111-g) 
are considered phenotypically homozygous, and those with 
FX activity levels of approximately 50% are considered phe- 
notypically heterozygous. 
koktion and ~haFacterization of the Mutant FX Gene 
Southern blot analysis of a patient’s (111/4) EcoRI-digested 
genomic DNA probed with a cDNA containing the whole 
coding sequence showed bands at 7.5,5.2,2.8, and 2.5 kilobase. 
The same bands were seen with genomic DNA from a non- 
related control (data not shown). Thus, there was no evidence 
of gross gene deletion or rearrangement in the patient’s FX 
gene. The nucleotide sequence for all exons and for the exon/ 
intron junctions was determined from patient 111/4. Sequence 
analysis revealed two differences between this sequence and 
the normal FX cDNA sequence. One mismatch was found at 
bp 91 of exon II (bp 160 of the coding region of the cDNA) 
(Fig. 4). The G-A change at the first nucleotide of codon 14 
results in the substitution of a lysine (AAA) for a glutamic 
acid residue (GAA), which normally undergoes y-carboxyla- 
tion to form a Gla residue. The mutation abolishes a naturally 
occurring Z’aqI restriction site with the sequence 5’-TCGA- 
3’ by changing the first base of the 3’ palindromic sequence 
to an adenosine (5’-TCAA’3’) (Fig. 2). Thus, genomic exon 
11986 Molecular Defect in FX Vorarlberg 
Factor X *Vorarlberg* 
G A T C 
FIG. 4. Sequence analysis of exon II of Factor X Vorarlberg. 
normal faotor X 
The G-A transition at the first nucleotide of codon 14 changes Glui4 
to Lys. 
II fragments amplified from the mutant allele cannot be cut 
with 7bqI. Enzymatically amplified and digested exon II 
fragments (Fig. 1) from the phenotypically homozygous family 
members III/l, 111/4, and III/9 uniformly show a single band 
at 185 bp representing the uncut exon II fragment. Therefore, 
these patients are genetically homozygous for the defect in 
exon II. 
Phenotypically heterozygous family members (IV/l, IV/5, 
IV/g, IV/lo, and IV/ll) display three bands: a band of 185 
bp which is also seen in homozygous patients and represents 
DNA amplified from a mutant allele, and bands of 84 and 101 
bp representing the cut exon II fragment amplified from a 
normal allele. Thus, these patients are heterozygous for the 
defect in exon II. Complete cutting occurs when exon II is 
amplified from a normal control. 
A second mismatch was detected at bp 57 of exon V (bp 
424 of the cDNA coding sequence). The G-+A change at the 
first bp of codon 102 results in the replacement by lysine 
(AAG) of glutamic acid (GAG) (Fig. 3). This mutation abol- 
ishes a naturally occurring MnH site. The non-palindromic 
sequence within the recognition site for MnH (5’-(N7)GAGG- 
3’) is changed to AAGG. Therefore, genomic exon V frag- 
ments amplified from the mutant allele cannot be cut with 
itf&I. Enzymatically amplified and digested exon V fragments 
from the phenotypically homozygous family members III/l, 
111/4, and III/9 uniformly show three different bands: one 
band of 149 bp, representing uncut exon V fragments from a 
mutant allele and bands at 58 and 91 bp representing cut 
exon V fragments from a normal allele (Fig. 1). Therefore, 
these family members are heterozygous for the defect in exon 
V. The same bands were obtained when exon V fragments 
were amplified and digested from the phenotypically hetero- 
zygous family members. Thus, they too are heterozygous for 
the defect in exon V. Complete cutting occurs when DNA is 
amplified from a normal control. 
Analysis of the pedigree (Fig. 1) shows that there are at 
least two mutant alleles in this family. One mutant allele 
carries the defect in exon II and the defect in exon V. The 
other mutant allele is defective in exon II but has a normal 
sequence in exon V. The possibility of a third mutant allele, 
normal in II but carrying the mutation in exon V, exists but 
cannot be proved or disproved based on the available kindred 
data. Family members who are phenotypically homozygous 
are genetically homozygous only for the defect in exon II. 
They are heterozygous for exon V. 
Isolation of FX (Normal and Vorarlbergj 
FX Vorarlberg and normal FX were isolated from BaCIZ- 
precipitated plasma using three different antibody columns: 
1) a rabbit polyclonal anti-human FX antibody; 2) a mono- 
clonal anti-FX antibody; and 3) a calcium-dependent rabbit 
polyclonal anti-human FX antibody. FX Vorarlberg and nor- 
mal FX from any of the three antibodies ran as a single band 
on unreduced SDS-polyacrylamide gel electrophoresis with 
an apparent Mr of 70,000 and were both processed into their 
two-chain forms under reducing conditions, with an apparent 
Mr for the heavy chain of 47,000 (Fig. 5). Amounts of material 
loaded onto the gel were insufficient to allow visualization of 
the light chain, which stains poorly with silver stains. While 
not quantitated precisely, the yields from patient plasma for 
the three columns were similar, suggesting that factor X 
Vorarlberg exists as one population in patient plasma rather 
than two, i.e., one responsive to Ca’+ conformational changes 
and the other refractory to such changes. Still, to avoid 
isolating a subpopulation of factor X Vorarlberg, the non- 
Ca’+-dependent antibody columns were used for purification. 
Gla Analysis 
Amino acid analysis showed that neither the Gla content 
nor the /3-hydroxyaspartic acid content of FX Vorarlberg 
differed significantly from the content of normal FX (isolated 
by the identical procedures). FX Vorarlberg analyzed (as 
described under “Experimental Procedures”) for 5.9 mol of 
Gla/mol of protein as compared with 6.3 mol of Gla/mol of 
normal factor X. The ratio of Glas in Vorarlberg to Glas in 
normal FX of 0.93 is almost exactly the value that would be 
expected (0.91) if a single Gla residue were removed from 
normal factor X. These results indicate that the substitution 
of Lys for Glu14 does not lead to a marked reduction in the 
Gla content of circulating factor X Vorarlberg. 
FX-dependent Coagulnnt Activity of FX Vorarlberg Plasma 
To determine coagulant activity of FX Vorarlberg plasma, 
human FX-deficient plasma was mixed with FX Vorarlberg 
(or normal) plasma and the PT, APTT, and RVV-times 
determined (Table II). Using the PT, FX Vorarlberg plasma 
has a FX clotting activity of 5% of normal. Using the aPTT, 
FX Vorarlberg plasma has a FX clotting activity of 25% of 
normal. When RVV is used to activate FX in plasma, FX 
Vorarlberg has a FX clotting activity of 15% of normal FX. 
lZM34 
LNonwducedJ LReducedJ 
FIG. 5. SDS-polyacrylamide gel electrophoresis of normal 
FX and FX Vorarlberg. FX was isolated from plasma using a 
polyclonal antihuman FX antibody. The gel was run under both 
reducing and nonreducing conditions and stained with silver. The 
apparent MC under nonreducing conditions (lanes 1 and 2) is 70,000; 
under reducing conditions (knes 3 and 4) the heavy chain has an 
apparent Mr of 47,000. 
TABLE II 
Cougulant actiuity of factor X Vorarlberg relative to normal fuctor X 
Assay Patient plasma Reconstituted plasma’ 
Antigen 0.20 1.00 
PT 0.05 0.15 
aPTT 0.25 1.00 
RVV 0.15 1.00 
’ Purified factor X (normal or Vorarlberg) was added to factor X- 
deficient plasma. 
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FX antigen was reduced to 20% of normal in the FX Vorarl- 
berg plasma. 
Coagukznt Activity of Purified FX VOFaF~beFg 
Since the antigen levels were reduced in patient plasma, to 
determine the coagulant activity of the purified FX Vorarl- 
berg, identical amounts of the purified FX Vorarlberg protein 
or normal FX were added to human FX-deficient plasma and 
the PT, the APTT, and the RVV-times of these plasmas were 
measured (Table II). Using the PT as a measurement of the 
FVIIa/TF-dependent, extrinsic pathway of blood coagulation, 
purified FX Vorarlberg has a clotting activity of 15% of 
normal. Using either the aPTT or RVV assays, purified FX 
Vorarlberg has a FX clotting activity of 100% of normal. 
Activation of Purified FX vorarberg 
The reduced activity of FX Vorarlberg in the PT could be 
due either to a defect in the activation of FX Vorarlberg by 
FVIIa/TF or to a defect of the activated factor thus formed. 
To characterize the interaction of purified FX Vorarlberg 
with the enzymes FVIIa, FIXa, and RVV, the initial rate of 
activation of purified FX Vorarlberg was compared with the 
initial rate of activation of normal FX using the chromogenic 
substrate Spectrozyme FXa. The increase in absorbance when 
FXa cleaves the chromogenic substrate is proportional to the 
FXa generated by the cleavage of the enzymes. All activations 
were performed at room temperature with Ca’+ concentration 
of 5 mM (the same Ca*+ concentration used in the coagulant 
assays). 
Activation with FVZZa-Using a molar excess of human 
recombinant FVIIa in the presence of a tissue factor source 
(Ortho brain thromboplastin), the rate of activation of FX 
Vorarlberg was 15% of the rate of activation of normal FX 
(Table III). 
Activation with FZXa-Using a molar excess of human 
FIXa/FVIIIa and phospholipid vesicles, the rate of activation 
of FX Vorarlberg was 75% of the rate of activation of normal 
FX (Table III). 
Activation with RVV-When RVV was used to activate FX, 
no difference was observed in the rate of activation between 
FX Vorarlberg and normal FX (Table III). 
Ca2+ Dependence of FX Activation-Activation of FX by 
FIXa, FVIIa, and RVV is Ca*+-dependent. Lowering the Ca*+ 
concentration impedes the rate of activation in a character- 
istic, non-linear fashion. The molecular defect in FX Vorarl- 
berg affects a potential Ca*+-binding residue. We therefore 
compared the rate of activation of FX Vorarlberg and normal 
FX at different Ca’+ concentrations ranging from 0.5 to 5 
mM. Fig. 6 shows the Ca*+ dependence of FX activation by 
FVIIa, FIXa, and RVV. The highest rate of activation of 
normal FX is set as 100%. 
Activation by FVZZa-Normal FX showed a loss in the rate 
of activation below 3.5 mM Ca’+ and was completely inactive 
at 0.5 mM Ca*+. FX Vorarlberg showed a rate of activation of 
15% of normal at 5 mM ca*+ and 3.5 mM Ca*+ ad had an 
TAELE III 
Activity of factor X Vorarlberg relative to normal factor X 
Activator Rate of activation’ Prothrombin converting activity of FXa* 
RVV 1.00 1.00 
FIXa/FVIIIa/PL 0.76 1.00 
FVIIa/TF 0.17 1.00 
’ Rates determined in presence of 5 mM Ca2+. 
’ Equal concentrations of factor Xa and factor Xa Vorarlberg used 
in assay. 
0 1 2 3 4 5 6 
I.20 , I 
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ICa++l (rnMJ 
FIG. 6. Calcium ion dependence for activation of factor X 
Vorarlberg. Factor X (0) or factor X Vorarlberg (W) was activated 
in the presence of factor IXa, factor VIIIa, and phosphoIipid vesicles 
(A), factor VIIa and tissue factor and the indicated concentration of 
calcium ion (B), or Russell’s viper venom (C). The activations were 
done as described under “Experimental Procedures.” The rate of 
factor X activation (relative to the highest value of normal factor X) 
is plotted uersus the concentration of calcium ion. Note that in A the 
calcium ion concentration extends to 8 mM. 
immediate loss of activity below 3.5 mM Ca’+ (Fig. 6B). When 
the relative rates of the FX activation were used (normalized 
to 100% at 5 mM Ca*+), no difference in the Ca’+ dependence 
of FX Vorarlberg and normal FX was observed. 
Activation by FZXa-Beginning at a concentration of 5 mM 
Ca’+, normal FX showed a slightly increasing rate of activa- 
tion until a Ca’+ concentration of 2 mM, with an immediate 
loss of activity below 2 mM Ca2+. FX Vorarlberg had a rate of 
activation that was slightly reduced compared with normal at 
5 mM Ca*+ (Fig. 6A). Increasing the Ca*+ concentration to 7 
mM resulted in a slight loss of activity. Below a Ca’+ concen- 
tration of 5 mM the rate of activation dropped immediately 
and was 10% at 3 mM Ca’+. Comparison of the relative rates 
of FX activation showed that the Ca’+ affinity of FX Vorarl- 
berg is decreased. 
Activation by RVV-Normal FX showed a slight increase 
in the rate of activation from 5 mM Ca’+ to 2 mM and lost 
activity immediately below that. FX Vorarlberg was normally 
active at 5 mM but lost activity below 5 mM ca*+ (Fig. 6C). 
The slopes of normal FX and FX Vorarlberg roughly paral- 
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leled each other but were separated by a difference in the 
Ca*+ concentration of approximately 3 mM. 
Conversion of Prothrombin by FXa 
To determine the activity of activated FX Vorarlberg (FXa 
Vorarlberg) toward prothrombin, normal FX and FX Vorarl- 
berg were activated with FVIIa, FIXa, or RVV. Identical 
amounts of the activated normal FX or FX Vorarlberg were 
then used to convert prothrombin to thrombin. At a Ca*+ 
concentration of 5 mM, the activity of FX Vorarlberg was 
100% of normal FX, irrespective of the method of activation 
of FX (Table III). 
Ca’+ Dependence of the Conversion of Prothrombin by FXa 
To determine the activity of FXa Vorarlberg and normal 
FXa at different Ca*+ concentrations, FX (Vorarlberg and 
normal) was activated with RVV and then incubated with 
prothrombin at various Ca*+ concentrations (Fig. 7). Normal 
FXa showed a slight increase in the rate of activation of 
prothrombin from 5 to 1 mM Ca’+. Below a Ca’+ concentration 
of 1 mM, normal FXa showed an immediate loss of activity. 
FXa Vorarlberg showed a slight increase in the rate of acti- 
vation of prothrombin from 5 to 2 mM Ca*+. Below a Ca*+ 
concentration of 2 mM normal FXa showed an immediate loss 
of activity. The slopes of normal FX and FX Vorarlberg 
paralleled each other. However, FXa Vorarlberg had an ap- 
parent Caz+ affinity which was 0.5 mM lower than that of 
normal FX. 
Intrinsic Fluorescence Quenching 
The intrinsic fluorescence quench of FX (normal and Vor- 
arlberg) is shown in Fig. 8. Addition of Ca’+ to normal FX 
resulted in a continuous loss of intrinsic fluorescence until 
the Ca’+ concentration reached 2.5 mM. No further change in 
fluorescence was observed above this Ca*+ concentration. FX 
Vorarlberg showed the same loss of intrinsic fluorescence as 
normal FX until the Ca*+ concentration reached 1.5 mM. 
While further additions of Ca*+ decreased the fluorescence of 
normal FX, no further change was observed in FX Vorarlberg. 
DISCUSSION 
Analysis of the gene coding for FX Vorarlberg disclosed 
that a point mutation in exon II, which encodes the Gla 
domain, generates the coagulation defect in these patients. As 
the mutation is located within a naturally occurring TaqI 
restriction site, a clear distinction can be made between 
1.20 
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FIG. 7. Calcium ion dependence for prothrombin activation 
by factor X Vorarlberg.-Prothrornbin &as incubated with factor 
Xa (0) or factor Xa Vorarlherg (W). factor Va, phospholipid, and the - - - 
indicated concentration of calcium ion as described under “Experi- 
mental Procedures.” The rate of thrombin formation (relative to the 
highest value) is plotted ~erau.s the concentration of calcium ion. 
0 1 2 3 4 .5 8 
[Ca+ +I (ZIIM) 
FIG. 8. Intrinsic fluorescence of factor X Vorarlberg. Factor 
X (0) or factor X Vorarlberg (W) was titrated with the indicated 
concentration of calcium and the intrinsic fluorescence measured as 
described under “Experimental Procedures.” The fluorescence at 320 
nm (280 nm excitation) was plotted against the concentration of 
calcium added. The fluorescence is expressed as a ratio of the initial 
value (no calcium present). 
homozygous and heterozygous genotypes by checking for the 
TaqI restriction site in the amplified exon II fragments. We 
were able to show that family members who are genetically 
homozygous for the defect display a much more severely 
affected phenotype (i.e. homozygous phenotype) than family 
members who are genetically heterozygous. Thus, the two 
distinct classes of phenotype correspond to defects in either 
one or both alleles of exon II. 
The point mutation in exon V, present on one allele, does 
not appear to be the causative mutation. First, its appearance 
bears no relationship to the affected phenotype. Second, the 
affected residue (amino acid 102), in contrast to the one in 
the Gla domain, is not conserved at all among the vitamin K- 
dependent coagulation factors. The most likely possibility is 
that this amino acid change represents a polymorphism. 
The mutation on exon II affects the codon for Gl@, a y- 
carboxylated glutamic acid (Gla) residue, and results in the 
substitution of a lysine at this position. Gla analysis indicates 
that this substitution results in the loss in circulating FX 
Vorarlberg of only a single Gla residue. Thus, residue 14 in 
factor X does not appear to be critical for carboxylation of 
the remaining Gla residues. 
As is the case for the other vitamin K-dependent procoag- 
ulant proteins, T-carboxylation of glutamic acid residues in 
the amino-terminal portion of the molecule is required for the 
protein to have coagulant activity (1). It is not yet clear, 
however, how much of the Gla domain must be intact in order 
to preserve normal function; nor is it clear whether the 
intrinsic and extrinsic systems, which both result in the 
cleavage of a single bond in the heavy chain to generate FXa, 
depend in an equivalent manner on a fully carboxylated Gla 
region of X. It is known that complete removal of the Gla 
domain from factor X results in a species that cannot be 
activated by either VIIa/TF or IXa/VIIIa (35). Studies of the 
Gla domain of prothrombin have shown that loss of as few as 
3 Gla residues results in a deficient Ca*+-dependent confor- 
mational change associated with poor phospholipid binding 
(36). Hiskey et al., modifying specific Gla residues in pro- 
thrombin fragment 1, also reported poor phospholipid binding 
(37). The study of factor X Vorarlberg provides a method for 
defining the functional characteristics of a single specific Gla 
residue. 
Our initial characterization of the mutant protein was by 
clotting assays on patient plasma. Even this relatively crude 
measure demonstrated that activity in the extrinsic system 
(5% of normal), as measured by the PT, was markedly reduced 
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compared with the amount of protein present (20% of nor- 
mal). In contrast, the activities as measured in the intrinsic 
system (15%) and by Russell viper venom time (25%) were 
roughly equivalent to the antigen level. The reduction in 
activity in the extrinsic system might be due to either slowed 
activation or to reduced activity of the activated material. 
However, as shown in Table II, FXa Vorarlberg was fully 
active in prothrombin activation at 5 mM Ca*+, regardless of 
the pathway used to generate the activated factor X Vorarl- 
berg. Thus, the lower activity seen in the coagulant assays 
based on the PT (at 5 mM Ca*+) must be due to a reduced 
rate of activation of purified FX Vorarlberg compared with 
normal (see Table III), confirming that the defect indeed 
occurs in activation. 
Since the structural defect in factor X Vorarlberg occurs at 
Glai4, it seemed likely that the functional defect of slowed 
activation (by VIIa/TF) might be mediated through an alter- 
ation in Ca2+ ion binding by the defective factor X molecule. 
We therefore pursued two methods of examining Ca2+ binding 
to the mutant protein, the change in intrinsic fluorescence as 
a function of the Ca2+ concentration and Ca’+ dependence of 
the rate of activation of factor X Vorarlberg by the three 
different systems (intrinsic, extrinsic, RVV). 
In the presence of Ca2+, factor X undergoes a conforma- 
tional change required for activity in prothrombin activation. 
This Ca’+-dependent conformational change can be followed 
by measuring changes in intrinsic fluorescence of the molecule 
as a function of Ca’+ concentration. As shown in Fig. 8, the 
fluorescence quench of FX Vorarlberg is less than that exhib- 
ited by normal FX, suggesting that the conformational change 
in FX Vorarlberg is incomplete compared with that which 
normally occurs. 
The data on rates of activation as a function of Ca2+ 
concentration provide further evidence that the slowed acti- 
vation by VIIa/TF at 5 mM Ca’+ is mediated through an 
alteration in the Ca2+-dependent rates of activation. While 
activation rates are in a physicochemical sense a more indirect 
means of studying conformation than fhrorescence quenching, 
these rates are physiologically perhaps more relevant. Two 
conclusions can be drawn from the data in Figs. 6 and 7. In 
the plots of activation by RVV, IXa-VIIIa, and the activation 
of prothrombin, it is clear that FX Vorarlberg requires in- 
creased calcium concentration in order to reach the same 
activation rates as normal FX. Stated differently, the confor- 
mation required for full activity can be achieved but only at 
a higher Ca2+ concentration. The plot for VIIa/TF, on the 
other hand, represents a different situation. Even at optimal 
Ca2+ concentrations, the rate of FX Vorarlberg activation is 
only 15% of normal. Raising the Ca2+ concentration does not 
overcome this defect. Thus, our experiments suggest that 
carboxylation at Glar4 and the resulting conformational 
change are more critical for VIIa/TF-mediated activation of 
X than for IXa-VIIIa-catalyzed activation. This in turn sug- 
gests that the two complexes almost certainly have different 
sites of interaction with FX, despite the fact that they cleave 
FX at the same bond. It is not possible to determine from 
these data whether the reduced rate of activation by VIIa-TF 
depends specifically on the absence of the Gla at residue 14, 
or whether it results because Ca*+ binding is less than maxi- 
mal (i.e. a point mutation at any other Gla residue would have 
a similar effect). Further study of this and of other proteins 
with mutations in the Gla region should prove informative 
from this standpoint. 
Acknowledgments-We thank Dr. Darrel W. Stafford for providing 
the FX cDNA, and Gwyn Cutsforth and Dr. Dan Powers for the 
generous gift of factor V and RVV. We also thank Dr. Kenneth Mann 
and Dr. William Church for supplying immobilized monoclonal an- 
tifactor X antibody. 
REFERENCES 
1. Jackson, C. M., and Nemerson, Y. (1980) Arznu. Reu. &&hem. 49, 765- 
811 
2. Di Scipio, R. G., Hermodson, M. A., Yates, S. G., and Da&, E. W. (1977) 
Biochemistry 16,698-706 
3. Fujikawa, K., Coan, M. H., Legaz, M. E., and Davie, E. W. (1974) Biochem- 
istry 13,5290-5299 
4. Radcliffe, R., and Nemerson, Y. (1974) J. Viol. Chem. 250,388-395 
5. Jesty, J., Spencer, A. K., Nakashima, Y., Nemerson, Y., and Konigsberg, 
W. (1975) J. Biol. Chem. 250,4497-5404 
6. McMullen, B. A., Fujikawa: K., Kisiel, W:, Sasagawa, T., Howard, W. N., 
Kwa, E. Y., and Weinsteq B. (1983) Bto&mi&y 22, 2875-2884 
7. Leytus, S. P., Chung, D. W.,. Kisiel, W., Kurachi, K., and Davie, E. W. 
(1984) Proc. Natl. Acad. SCL U. S. A. 81, 3699-3702 
8. Fung, M. R.. Hav. C. W,. and MacGillivrav. R. T. A. (1985) Proc. N&L 
A&d. Sci. ‘U. ; 
9. Kaul, R. K., Hi 
Gene (Amst.) 
10. Royle, N. J., Fc 
(1986) 
s: A. 62,3591-3595 - 
ldebrand, B., Roberts, S., and Jagadeeswaran, P. (1986) 
Al 2llL-?lA 
trig, M. R., MacGillivray, R. T. A., and Hamerton, J. L. 
Cytogenet. CellGene 41,185-188 
P., Foster, D. C., Kurachi, K., and Davie, E. W. (1986) Bio&m- 
hy 2& 5098-5102 
11. Le,ytus, S 
12. Houeie. C.. Barrow. E. M.. and Graham. J. B. (1957) J. Clin. Znuest. 36. 
AiLiW3 --- ~~- 
13. Denson, K. W. E., Lurie, A., DeCataldo, F., and Manucci, P. M. (1970) Br. 
J. HaematoL l&317-327 
14. Fair, D. S., and Edgington, T. S. (1985) Br. J. Haematol. 59, 235-248 
15. Fair, D. S., Plow, E. F., and Ed&ton, T. S. (1979) J, Clin. Znuest. 648, 
mA-RQA --  -“- 
16. Blin, N., and Stafford, D. W. (1976) Nucleic Acid Res. 3, 2303-2308 
17. Southern, E. (1975) J. Mol. Biol, 98,503-517 
18. Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. 
T., Mullis, K. B., and Erlich, H. A. (1988) Science 239,487-491 
19. Fung, M. R. (1988) &f&&or Genetics ofZ3bod Coagulation Factor X. Ph.D 
dissertation, University of British Columbia, Vancouver, Canada 
20. Huang, M. N., Kasper, C. K., Roberts, H. R., Stafford, D. W., and High, 
K. A. (1989) Blood 73,7%721 
21. Church. W. R.. Messier. T. L.. Tucker. M. M.. and Mann. K. G. (1988) 
Blooci72, ltill-1921 
22. Monroe, D. M., Sherrill, G. B., and Roberts, H. R. (1988) AnaL Eiochem. .w‘, ,-- ,‘,F 
1 ,z, ‘IL,-SXJ 
23. Griffith, M. J., Breitkreutz, L., Trapp, H., Briet, E., Noyes, C. M., Lundblad, 
R. L., and Roberts, H. R. (1985) J. Clin. Znuest. 76,4-10 
24. Church, F. C., and Whinna, H. C. (1986) Anal. Lliochem. 157,77-83 
25. LeStowgeon, W. M., and Beyer, A. L. (1977) Methods Cell. BioL 16,387- 
406 
26. Morrissey, J. H. (1981) Anal. Biochem. 117,307 
27. Monroe, D. M., McCord, D. M., Huang, M. N., High, K. A,, Lundblad, R, 
L., Kasper, C. K., and Roberts, H. R. (1989) Blood 73, 1540-1544 
28. Furie, B. C., and Furie, E 
29. Law&, C. B. (1966) Anal. Biocj 
30. Jo~es~-~~-~.~~rif~t~, M. J., Mt -. - 
1. (1976) h4ethods Enzymol. 45,‘191-205 
km. 15,45-52 
xme, D. M., Roberts, H. R., and Lentz, B. 
I%. (IY&~) mocnemrmy z4,8064-8069 
31. Nesheim, M. E., Prendergast, F. G., and Mann, K. G. (1979) Biochemistry 
l&996-1003 
32. Nelsestusn, G. L. (1976) J. Biol. Chem. 251,5648-5656 
33. Prendergast, F. G., and Mann, K. G. (1977) J. Biol. Chem. 252,840-850 
34. Price, P. A. (1983) Metkods Enzymol. 91, 13-17 
35. Morita, T., and Jacksot, C. M. (1986) J. BioL Chem. 261,4015-4023 
36. Malhotra, 0. P., Neshen, M. E., and Mann, K. G. (1985) J. Biol. Chem. 
260,279-287 
37. Zapata, G. A., Berkowitz, P., Noyes, C. M., Pollock, J. S., Deerfield, D. W., 
II, Pedersen, L. G., and Hiskey, R. G. (1988) J. Biol. Ckem. 263,8150- 
8156 
